Garr will present an update on the company's NSI-566 cell therapy clinical trials, including the FDA-approved chronic spinal cord injury Phase I; ALS Phase II; and the ischemic stroke Phase I/II in , which the company expects to initiate this month.
http://www.biospace.com/news_story.aspx?StoryID=287025&full=1
http://www.biospace.com/news_story.aspx?StoryID=287025&full=1
No comments:
Post a Comment